Does body mass index or subcutaneous adipose tissue thickness affect interfraction prostate motion in patients receiving radical prostate radiotherapy?

被引：2

作者：

Rogers, Jonathan ^{[1
]}

Welgemoed, Camarie ^{[1
]}

Gujral, Dorothy ^{[1
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Dept Radiotherapy, Fulham Palace Rd, London W6 8RF, England

来源：

JOURNAL OF RADIOTHERAPY IN PRACTICE | 2016年 / 15卷 / 04期

关键词：

body mass index; image-guided radiotherapy; prostate motion; subcutaneous adipose tissue;

D O I：

10.1017/S1460396916000364

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Aim: It is unclear whether body mass index (BMI) is a useful measurement for examining prostate motion. Patient's subcutaneous adipose tissue thickness (SAT) and weight has been shown to correlate with prostate shifts in the left/right direction. We sought to analyse the relationship between BMI and interfraction prostate movement in order to determine planning target volume (PTV) margins based on patient BMI. Materials and methods: In all, 38 prostate cancer patients with three implanted gold fiducial markers in their prostate were recruited. Height, mass and SAT were measured, and the extent of interfraction prostate movement in the left/right, superior/inferior and anterior/posterior directions was recorded during each daily fiducial marker-based image-guided radiotherapy treatment. Mean corrective shift in each direction for each patient, along with BMI values, were calculated. Results: The median BMI value was 28.4 kg/m(2) (range 21.4-44.7). Pearson's product-moment correlation analysis showed no significant relationship between BMI, mass or SAT and the extent of prostate movement in any direction. Linear regression analysis also showed no relationship between any of the patient variables and the extent of prostate movement in any direction (BMI: R-2 = 0.006 (rho = 0.65), 0.002 (rho = 0.80) and 0.001 (rho = 0.86); mass: R-2 = 0.001 (rho = 0.87), 0.010 (rho = 0.54) and 0.000 (rho = 0.99); SAT: R-2 = 0.012 (rho = 0.51), 0.013 (rho = 0.50) and 0.047 (rho = 0.19) for shifts in the X, Y and Z axis, respectively). Patients were grouped according to BMI, as BMI < 30 (n = 25, 65.8%) and BMI >= 30 (n = 13, 34.2%). A two-tailed t-test showed no significant difference between the mean prostate shifts for the two groups in any direction (rho = 0.320, 0.839 and 0.325 for shifts in the X, Y and Z axis, respectively). Findings: BMI is not a useful parameter for determining individualised PTV margins. Gold fiducial marker insertion should be used as standard to improve treatment accuracy.

引用

页码：334 / 340

页数：7

共 36 条

[1]

Center M.M., Jemal A., Lortet-Tieulent J., Et al., International variation in prostate cancer incidence and mortality rates, Eur Urol, 61, 6, pp. 1079-1092, (2012)

[2]

Jackson A., Murthy V., Dearnlaley D., External beam radiotherapy for prostate cancer, Radiotherapy in Practice: External Beam Therapy, pp. 181-211, (2006)

[3]

Formiguera X., Canton A., Obesity: Epidemiology and clinical aspects, Best Pract Res Clin Gastroenterol, 18, 6, pp. 1125-1146, (2004)

[4]

Wong J.R., Gao Z., Merrick S., Uematsu M., Wilson P., Cheng C., Subcutaneous adipose-tissue thickness is a more accurate indicator of the variation of the interfraction prostate position throughout radiation treatment than patient's weight or body mass index, Int J Radiat Oncol Biol Phys, 72, 1, (2008)

[5]

Wong J.R., Gao Z., Merrick S., Et al., Potential for higher treatment failure in obese patients: Correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images, Int J Radiat Oncol Biol Phys, 75, 1, pp. 49-55, (2009)

[6]

Millender L.E., Aubin M., Pouliot J., Shinohara K., Roach M., Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 59, 1, pp. 6-10, (2004)

[7]

Maruoka S., Yoshioka Y., Isohashi F., Et al., Correlation between patients' anatomical characteristics and interfractional internal prostate motion during intensity modulated radiation therapy for prostate cancer, Springerplus, 4, (2015)

[8]

Piotrowski T., Kaczmarek K., Jodda A., Et al., Image guidance procedures in radiotherapy for prostate cancer and the influence of body mass index, J Radiother Pract, 13, pp. 410-417, (2014)

[9]

Butler W.M., Morris M.N., Merrick G.S., Kurko B.S., Murray B.C., Effect of body mass index on intrafraction prostate displacement monitored by real-time electromagnetic tracking, Int J Radiat Oncol Biol Phys, 84, 2, pp. e173-e179, (2012)

[10]

Chen Y.J., Lee R.J., Handrahan D., Sause W.T., Intensitymodulated radiotherapy using implanted fiducial markers with daily portal imaging: Assessment of prostate organ motion, Int J Radiat Oncol Biol Phys, 68, 3, pp. 912-919, (2007)

← 1 2 3 4 →